Denali Therapeutics Inc 's Income per employee grew in the third quarter 2026 on a trailing twelve month basis to $ 393,668, the income was higher than average, indicating higher productivity of the company's employees. The Healthcare sector has seen employees of 22 other companies achieving higher income per employee. While Denali Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2065 to 2094.
Denali Therapeutics’ Recent Announcements: Key Facts and Implications Denali Therapeutics Inc., a cutting-edge biopharmaceutical company, is making significant strides in addressing complex and rare diseases through innovative therapeutic approaches. Recent press releases from the company detail two crucial developments: the extension of the FDA review timeline for the Biologics License Application (BLA) for tividenofusp alfa, a promising treatment for mucopolysaccharidosis type II (MPS II), and the initiation of a Phase 2a clinical study of the LRRK2 inhibitor BIIB122 (DNL151) for LRRK2-associated Parkinson s disease (LRRK2-PD). Key Developments: 1. FDA Review Extension for Tividenofusp Alfa: - On October 13, 2025, Denali Therapeutics announced that the FDA extended the review timeline for its BLA seeking accelerated approval of tividenofusp alfa from January 5, 2026, to April 5, 2026. This extension reflects the agency’s need for additional time to assess the data supporting the application for this treatment of Hunter syndrome, a rare lysosomal storage disorder characterized by progressive morbidity.
Companies with similar Income per Employee for 12 month ending Sep 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.